Drug Use Clinical Trial
Official title:
Bioequivalence Study of 3 mg Glimepiride Tablet in Indonesia Healthy Subjects
The study was conducted toinvestigate whether the bioavailability of 3 mg Glimepiride Tablet Manufactured by PT. Harsen Laboratories was bioequivalent to the reference product, 3 mg Amaryl® Tablet Manufactured by PT. Aventis Indonesia Pharma, Indonesia.
The study was conducted following an oral administration of one tablet of the test drug (3 mg Glimepiride Tablet) or one tablet of the reference drug (3 mg Amaryl® Tablet ). Blood samples were drawn before dosing (0 h) and at 15, 30, 45 minutes, and 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 9, 12, 18, 24, and 30 hours after drug administration. The entire subjects were given 60 mL of 20% glucose solution to minimize hypoglycemic effects at 15, 30, 45 minutes, and 1, 1.25, 1.5, 1.75, 2, 2.25, 2.5, 2.75, 3, 3.25, 3.5, 3.75 and 4 hours after drug administration. Following a washout period of one week, this procedure was repeated using the alternate drug. The plasma concentrations of glimepiride were determined by means of LC-MS/MS system. The LLOQ is 1.99 ng/mL of glimepiride. The pharmacokinetic parameters used in this study were area under the concentration-time curve of glimepiride from time zero to 30 hours (AUCt), area under the concentration-time curve from time zero to infinite (AUCinf), maximum concentration (Cmax), time required to reach the maximum concentration (tmax) and the elimination half life (t½). ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT06395129 -
Low Dead-space Injecting Equipment Distribution Program for People Who Inject Drugs in Low- and Middle-income Countries
|
||
Completed |
NCT02293057 -
Gender-Responsive Drug Use Treatment for Juvenile Justice Girls
|
N/A | |
Completed |
NCT01941108 -
Technology-Enhanced Peer Navigation to Improve IDUs' Engagement in HIV Care
|
N/A | |
Completed |
NCT01380613 -
Neighborhoods, Networks, Depression, and HIV Risk
|
Phase 2 | |
Withdrawn |
NCT00914719 -
Alcohol Use and Sexual Risk: An Intervention
|
N/A | |
Recruiting |
NCT03671629 -
Pharmacist Intervention to Reduce Drug-related Readmissions Among the Elderly
|
N/A | |
Completed |
NCT03290391 -
Linking Infectious and Narcology Care-Part II
|
Phase 4 | |
Completed |
NCT04008927 -
A Community-based Intervention Among Active Drug Users in Montpellier
|
N/A | |
Completed |
NCT03627546 -
HCV Seek, Test and Rapid Treatment for Young PWID
|
N/A | |
Not yet recruiting |
NCT03967262 -
Secondary Prevention and Recidivism Reduction in Trauma Patients
|
N/A | |
Completed |
NCT03079856 -
Drug Use and Sexual Risk Behaviors Among Emerging Adults in the ER
|
N/A | |
Completed |
NCT03855410 -
Preventing Cigarette Use Among Urban Youth Via an M-Health Primary Care Preventive Intervention
|
N/A | |
Terminated |
NCT02457949 -
The Impact of Alternative Social Assistance Disbursement on Drug-related Harm
|
N/A | |
Completed |
NCT06238154 -
Flurbiprofen Tablet vs Spray In Oral Soft Tissue Wounds
|
Phase 4 | |
Terminated |
NCT04436055 -
Intergenerational Effects of Paternal Periconceptional Cannabis and Other Drug Use (EPIC)
|
||
Recruiting |
NCT04717856 -
Evaluation of the Use of the GenXpert to Detect Hepatitis C RNA
|
N/A | |
Completed |
NCT00249496 -
Employment-based Reinforcement to Motivate Drug Abstinence in the Treatment of Drug Addiction. - 1
|
N/A | |
Recruiting |
NCT05597865 -
Assessing the Feasibility of Economic Approaches to Prevent Substance Abuse Among Adolescents
|
N/A | |
Completed |
NCT05553054 -
Drug Wastage : Observational Study in Intensive Care Units in France
|
||
Completed |
NCT03718520 -
The Influence of in Utero Cannabis Exposure on Neonatal Brain Morphology and Structural Connectivity
|